Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InnoCare OptoelectronicsTPE:6861 -10.00%66 Return-on-Tangible-Equity is 15.51% as of Dec. 2025, which is 43% below its 10-year median of 27.41. GuruFocus rates TPE:6861 with a GF Score™ of 66/100 and a GF Value™ of NT$85.82 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 759 Medical Devices & Instruments companies, InnoCare Optoelectronics ranks better than 70.22% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. InnoCare Optoelectronics's annualized net income for the quarter that ended in Dec. 2025 was NT$219 Mil. InnoCare Optoelectronics's average shareholder tangible equity for the quarter that ended in Dec. 2025 was NT$1,415 Mil. Therefore, InnoCare Optoelectronics's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 15.51%.
The historical rank and industry rank for InnoCare Optoelectronics's Return-on-Tangible-Equity or its related term are showing as below:
TPE:6861'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 11.19 Med: 27.41 Max: 54.76
Current: 11.43
During the past 8 years, InnoCare Optoelectronics's highest Return-on-Tangible-Equity was 54.76%. The lowest was 11.19%. And the median was 27.41%.
TPE:6861's Return-on-Tangible-Equity is ranked better than 70.22% of 759
companies
in the Medical Devices & Instruments industry
Industry Median: 4.04
vs TPE:6861: 11.43
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
InnoCare Optoelectronics Return-on-Tangible-Equity Related Terms
InnoCare Optoelectronics Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for InnoCare Optoelectronics's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:6861 vs ABT, SYK, MDT: Return-on-Tangible-Equity Comparison
For the Medical Devices subindustry, InnoCare Optoelectronics's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InnoCare Optoelectronics Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, InnoCare Optoelectronics's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where InnoCare Optoelectronics's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 15.51% mean?
InnoCare Optoelectronics (TPE:6861) has a Return-on-Tangible-Equity of 15.51% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on InnoCare Optoelectronics and its competitors. This is 43% below median its historical median of 27.41. Over the past decade, InnoCare Optoelectronics' Return-on-Tangible-Equity has ranged from 11.19 to 54.76. According to the industry distribution chart, InnoCare Optoelectronics ranks #226 out of 759 companies in the Medical Devices & Instruments industry, placing it in the top 29.8%.
Is InnoCare Optoelectronics' Return-on-Tangible-Equity too high?
InnoCare Optoelectronics' current Return-on-Tangible-Equity of 15.51% is 43% below median its 10-year median of 27.41. Over the past 10 years, this metric has ranged from a low of 11.19 to a high of 54.76. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.04. InnoCare Optoelectronics' value of 15.51% is 283.9% above this industry median. Based on the distribution chart, InnoCare Optoelectronics ranks #226 out of 759 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, InnoCare Optoelectronics has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does InnoCare Optoelectronics' Return-on-Tangible-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, InnoCare Optoelectronics ranks #226 out of 759 companies for Return-on-Tangible-Equity. This puts InnoCare Optoelectronics in the upper half of its industry. The industry median Return-on-Tangible-Equity is 4.04. InnoCare Optoelectronics' value of 15.51% is 283.9% above this benchmark. Historically, InnoCare Optoelectronics' own Return-on-Tangible-Equity has ranged from 11.19 to 54.76 over the past decade. While the company's 10-year median is 27.41 vs. the industry median of 4.04, InnoCare Optoelectronics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.04, based on 759 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. InnoCare Optoelectronics's current Return-on-Tangible-Equity of 15.51% is 283.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on InnoCare Optoelectronics and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InnoCare Optoelectronics's current Return-on-Tangible-Equity is 15.51%, which is 43% below median its own 10-year median of 27.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InnoCare Optoelectronics stock overvalued right now?
Based on GuruFocus' analysis, InnoCare Optoelectronics (TPE:6861) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$85.82, compared to a current price of NT$225.00 — trading 162.2% above its estimated fair value. The current Return-on-Tangible-Equity is 15.51%, which is 43% below median its 10-year median of 27.41 and 283.9% above the Medical Devices & Instruments industry median of 4.04. InnoCare Optoelectronics' overall GF Score™ is 66/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For InnoCare Optoelectronics (TPE:6861), the current Return-on-Tangible-Equity is 15.51% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InnoCare Optoelectronics (TPE:6861) Overvalued in 2026?
Based on GuruFocus' analysis, InnoCare Optoelectronics stock appears to be overvalued.
The current stock price of NT$225.00 is trading 162.2% above its estimated GF Value™ of NT$85.82.
GuruFocus considers InnoCare Optoelectronics to be Significantly Overvalued.
Key valuation signals for TPE:6861:
Return-on-Tangible-Equity: 15.51% (43% below median its 10-year median of 27.41)
GF Value™: NT$85.82 vs. price of NT$225.00 (162.2% above fair value)
Industry Position: 283.9% above the Medical Devices & Instruments median (#226 of 759)
No single metric tells the full story. See the TPE:6861 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InnoCare Optoelectronics Corp is mainly engaged in the manufacturing and sale of optical instruments and medical equipment. Its products include X-Ray flat panel detector devices, X-Ray flat panel detector modules, and others.
66GF Score
Get the complete analysis for TPE:6861
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6861 has been successfully added to your 
